Pancragen Peptide (Lys-Glu-Asp-Trp) 20mg

Pancragen has been studied for its potential to restore function of the pancreas in the context of aging and type 2 diabetes. Research has focused on its effects in animal models, examining both endocrine regulation and cellular differentiation in the pancreas.

Mechanisms of Action

In human embryonic pancreatic cell cultures, pancragen specifically stimulated the expression of differentiation factors (CXCL12, Hoxa3), especially in aged cells. This tissue-specific stimulation was more pronounced in older cultures, indicating a possible geroprotective mechanism.^[1]

Effects on Pancreatic Endocrine Function

In older animals, pancragen administration led to decreased basal insulin and C-peptide levels, increased glucose disappearance rates, and normalization of glucose, insulin, and C-peptide responses after glucose administration. These effects partially persisted for three weeks after stopping treatment.^[2]

Pancragen was effective in restoring age-related endocrine dysfunctions of the pancreas, suggesting its promise as a therapeutic agent for age-associated glucose intolerance and type 2 diabetes.^[2]

Effectiveness in Diabetes Models

In elderly patients with type 2 diabetes, pancragen administration led to significant reductions in fasting glucose, improved glucose tolerance, and decreased insulin resistance. These benefits were not observed in patients who did not receive pancragen, suggesting a specific therapeutic effect.^[3] 

In diabetic rats, pancragen normalized the adhesion of mesenteric capillary endothelium, suggesting protective effects on vascular function during early diabetes, though it did not affect capillary permeability.^[4] 

Oral pancragen produced a significant hypoglycemic effect during treatment, supporting its potential for blood glucose regulation in diabetes. The peptide also demonstrated homeostatic effects in diabetic conditions, further supporting its research potential.^[4]

References

1. Khavinson, V., Linkova, N., Polyakova, V., Kheifets, O., Tarnovskaya, S., & Kvetnoy, I. (2012). Peptides Tissue-Specifically Stimulate Cell Differentiation during Their Aging. Bulletin of Experimental Biology and Medicine, 153, 148-151. https://doi.org/10.1007/s10517-012-1664-1.
2. Goncharova, N., Ivanova, L., Oganian, T., Vengerin, A., & Khavinson, V. (2014). [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].. Advances in gerontology = Uspekhi gerontologii, 27 4, 662-7.
3. Korkushko, O., Khavinson, V., Shatilo, V., Antonyk-Sheglova, I., & Bondarenko, E. (2011). Prospects of Using Pancragen for Correction of Metabolic Disorders in Elderly People. Bulletin of Experimental Biology and Medicine, 151, 454-456. https://doi.org/10.1007/s10517-011-1354-4.
4. Khavinson, V., Gavrisheva, N., Malinin, V., Chefu, S., & Trofimov, E. (2007). Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bulletin of Experimental Biology and Medicine, 144, 559-562. https://doi.org/10.1007/s10517-007-0377-3.